Case series: CYP Inhibition and low dose ibrutinib for steroid-refractory chronic graft-versus-host disease

被引：1
|
作者：
De la Garza-Salazar, Fernando
Colunga-Pedraza, Perla Rocio
Coronado-Alejandro, Edgar Ulises
Gutierrez-Aguirre, Cesar Homero
Cantu-Rodriguez, Olga Graciela
Gomez-Almaguer, David [1 ,2 ]
机构：
[1] Univ Autonoma Nuevo Leon, Fac Med, Monterrey, Mexico
[2] Univ Autonoma Nuevo Leon, Hosp Univ Dr Jose Eleuterio Gonzalez, Hematol Serv, Internal Med Dept, Monterrey, Mexico
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷 / 03期
关键词：
chronic graft versus host disease; CYP; ibrutinib; itraconazole; low dose;
D O I：
10.1111/bjh.18712
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：573 / 576
页数：4
相关论文
共 50 条
  • [11] Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease
    Okamoto, M
    Okano, A
    Akamatsu, S
    Ashihara, E
    Inaba, T
    Takenaka, H
    Katoh, N
    Kishimoto, S
    Shimazaki, C
    LEUKEMIA, 2006, 20 (01) : 172 - 173
  • [12] Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease
    M Okamoto
    A Okano
    S Akamatsu
    E Ashihara
    T Inaba
    H Takenaka
    N Katoh
    S Kishimoto
    C Shimazaki
    Leukemia, 2006, 20 : 172 - 173
  • [13] Brentixumab vedotin for the treatment of steroid-refractory chronic graft-versus-host disease
    DeFilipp, Zachariah
    Li, Shuli
    Kempner, Maria
    Brown, Jami
    Del Rio, Candice
    Valles, Betsy
    Ballen, Karen
    Dey, Bimalangshu
    El-Jawahri, Areej
    McAfee, Steven
    Spitzer, Thomas
    Chen, Yi-Bin
    BONE MARROW TRANSPLANTATION, 2018, 53 : 398 - 398
  • [14] Conventional Versus Low Dose Rituximab in the Treatment of Steroid-Refractory Chronic Graft Versus Host Disease
    Rummage, Claire W.
    Watts, Nicole
    McGwin, Gerald
    Saad, Ayman
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S203 - S204
  • [15] Ruxolitinib treatment for steroid-refractory graft-versus-host disease
    Park, Han-Seung
    Lee, Je-Hwan
    Lee, Jung-Hee
    Choi, Eun-Ji
    Seol, Miee
    Lee, Young-Shin
    Kang, Young-Ah
    Jeon, Mijin
    Lee, Kyoo-Hyung
    BONE MARROW TRANSPLANTATION, 2019, 54 : 323 - 324
  • [16] Ruxolitinib for steroid-refractory acute graft-versus-host disease
    Toama, Wael
    Fiala, Mark
    Pusic, Iskra
    Westervelt, Peter
    Dipersio, John F.
    Schroeder, Mark
    TRANSPLANT INTERNATIONAL, 2020, 33 (02) : 244 - 246
  • [17] Pentostatin in steroid-refractory acute graft-versus-host disease
    Bolaños-Meade, J
    Jacobsohn, DA
    Margolis, J
    Ogden, A
    Wientjes, MG
    Byrd, JC
    Lucas, DM
    Anders, V
    Phelps, M
    Grever, MR
    Vogelsang, GB
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2661 - 2668
  • [18] Low dose alemtuzumab is effective in the treatment of severe steroid-refractory acute graft-versus-host disease
    Repp, R
    Claviez, A
    Gahn, B
    Schub, N
    Beck, C
    Helm, F
    Gramatzki, M
    BONE MARROW TRANSPLANTATION, 2006, 37 : S97 - S97
  • [19] Ruxolitinib Treatment of Steroid-Refractory Graft-versus-Host Disease in Children: A Case Series and Review of the Literature
    Yan, Wei-Ling
    Zhao, Fen-Ying
    Gu, Min-Er
    Liu, Nan
    Guo, Xiao-Ping
    Xu, Xiao-Jun
    PEDIATRIC DRUGS, 2023, 25 (05) : 577 - 584
  • [20] Ruxolitinib Treatment of Steroid-Refractory Graft-versus-Host Disease in Children: A Case Series and Review of the Literature
    Wei-Ling Yan
    Fen-Ying Zhao
    Min-Er Gu
    Nan Liu
    Xiao-Ping Guo
    Xiao-Jun Xu
    Pediatric Drugs, 2023, 25 : 577 - 584
12345